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cardiac hypertrophy, namely protein synthesis, NFAT and MAP kinase sig-
naling. Hence, this study was undertaken to identify a novel mechanism by
which AMPK can regulate cardiac hypertrophy.
Methods: Hypertrophy was induced in neonatal rat cardiomyocytes
(NRVMs) using PE for 24h and AMPK was chronically activated with
A769662. Hypertrophy was evaluated by immunostaining and cell surface
area measurement. In vivo cardiac hypertrophy was induced by Angiotensin II
(AngII) infusion by osmotic mini-pumps and AMPK was activated by met-
formin in drinking water. Protein expression, AMPK phosphorylation and O-
GlcNAc levels were evaluated by QPCR and western blot.
Results: First, we showed that PE-dependent cardiomyocyte hypertrophy
was accompanied by an increase in O-GlcNAc levels. This hypertrophy was
prevented by A769662 and this was associated with a decrease in O-GlcNAc
levels. Then, using hexosamine biosynthesis pathway activators, i. e
PUGNAc or glucosamine, we showed that increase in O-GlcNAc levels was
able to reverse the anti-hypertrophic effect of AMPK activation in NRVMs.
Similar results were obtained in adult rat cardiomyocytes. On the other
hand, inhibition of hexosamine biosynthesis pathway by Azaserine or DON
inhibited PE-induced cardiomyocyte hypertrophy and this effect was
reversed by PUGNAc or glucosamine. In vivo experiments confirmed these
in vitro data. Indeed, metformin was able to reduce cardiac hypertrophy and
this correlated with a decrease in O-GlcNAc levels in WT mice but not in
AMPKα2 knockout mice.
Conclusion: Collectively, our results suggest that AMPK regulates cardiac
hypertrophy mainly by inhibiting O-GlcNAcylation signaling. AMPK and O-
GlcNAcylation signaling could be putative new therapeutic targets for treat-
ment of cardiac hypertrophy.
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T-type voltage-gated calcium channels (T-VGCC) are involved in the
regulation of pulmonary arterial tone. Besides their roles in smooth muscle
cell contraction, we investigate if T-VGCC could control vascular relaxation
via endothelial calcium signaling regulation in mouse pulmonary arteries.
Immunofluorescence labeling indicates that endothelial cells (as well as
smooth muscle cells) express T-VGCC proteins (Cav3.1 and Cav3.2 isotypes).
We show that nitric oxide (NO)-dependent relaxation induced by acetylcho-
line is reduced in the presence of T-VGCC antagonists (mibefradil, NNC 55-
0396) and in Cav3.1 knock-out mice. Acetylcholine induces an endothelial
intracellular calcium increase which is reduced by the same types of inhibi-
tors. By contrast, endothelium dependent relaxation induced by beta 2 adren-
ergic stimulation (with procaterol), which is calcium independent, is not
inhibited by mibefradil or in Cav3.1 knock-out mice. Furthermore, in patho-
logical condition (pulmonary hypertension induced by a chronic hypoxia),
acetylcholine-mediated relaxation is reduced and even more in Cav3.1 knock-
out mice. In summary, in mice pulmonary arteries, acetylcholine and calcium-
dependent dilatation require T-VGCC. The present findings suggest that cal-
cium influx through T-VGCC mediate a dual effect in pulmonary artery: a
contraction when it occurred in smooth muscle cells and a dilatation when it
occurred in endothelial cells.
0176
Smooth muscle specific Rac1 deficiency induces hypertension by over
activation of RhoA/Rho-kinase signaling pathway
Gwennan André, Gervaise Loirand, Vincent Sauzeau
Institut du Thorax, INSERM U1087, Nantes, France
The small GTPase RhoA and its target, Rho kinase, play essential role
in both blood pressure regulation and vascular smooth muscle contraction.
Increasing evidence implicates over activation of this signaling pathway as
a critical event in the pathogenesis of hypertension. Interestingly, it has
been recently described that Rac1 could antagonize RhoA-dependent func-
tions. However, the role of Rac1 in the regulation of vascular tone and
blood pressure is not fully elucidated. Here we assessed the hypothesis
that smooth muscle Rac1 participates in the control of blood pressure. To
define the role of vascular smooth muscle cells (vSMC) Rac1 in vivo in
the control of blood pressure, we generated inducible, smooth muscle
(SM)-specific Rac1 knockout mice (SM-Rac1-KO) and analyzed cardio-
vascular parameters. Following induction of Rac1 deletion, SM-Rac1-KO
mice rapidly develop high systolic blood pressure (+15±2 mmHg, n=19,
p=0.02). Treatment with the Rho kinase inhibitor fasudil decreases systolic
arterial pressure to a level similar in control and SM-Rac1-KO mice sug-
gesting that RhoA/Rho kinase signaling is involved in the rise in systolic
blood pressure induced by SM-Rac1 deletion. This is confirmed by immu-
noblot analysis in aorta that reveals an increase of activated RhoA (348±
19% of control, n=4, p<0.05) and Rho-kinase activity (390±25% of con-
trol, n=4, p<0.05) in SM-Rac1-KO compared to control mice. This over-
activation of RhoA signaling in SM-Rac1-KO mice is associated with a
75%-reduction of the inhibitory phosphorylation of RhoA on Ser188 com-
pared to control mice. At functional level, while NO production is not
modified, NO-dependent vasodilation is decreased in SM-Rac1-KO
arteries (≈  56% of control). By in vitro experiments in vSMC, we demon-
strate that the loss of Rac1 leads to a defective production of cGMP and a
down-regulation of the cGMP-dependent kinase-mediated inhibition of
RhoA/Rho kinase signaling. These results thus identified a blood pressure-
lowering effect of vSMC Rac1, that tonically antagonizes RhoA/Rho
kinase activity to modulate arterial tone and blood pressure through
cGMP/ cGMP-dependent kinase pathway.
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Estradiol (E2) regulates gene transcription through nuclear Estrogen
Receptor alpha (ERα) thanks to two Activation Functions, AF-1 and AF-
2, but can activate membrane ERα and thereby rapid « non genomic »
signals. Some tissue-specific stimulatory roles of these ERα functions
have already been described: for instance ERαAF1 and membrane ERα
activation are each necessary and sufficient to induce endometrial epithe-
lial proliferation and to accelerate endothelial healing respectively in
response to E2.
E2 can also inhibit vascular smooth muscle cell proliferation, but the
mechanisms of this action are poorly recognized. Using a mouse model of
femoral artery injury, we found that 1) E2 prevents intimal smooth muscle
hyperplasia. 2) Selective inactivation of ERα in smooth muscle cells abrogates
this protective action, whereas its endothelial and hematopoietic inactivation
did not alter this effect. 3) Estrogen dendrimer conjugate, a selective activator
of membrane ERa, fail to prevent intimal hyperplasia. 4) E2 does not inhibit
post-injury arterial smooth muscle cell proliferation in mice selectively defi-
cient in ERαAF1 (through deletion of the N-terminal A/B domain which har-
bors this function), demonstrating that ERαAF1 is necessary to mediate this
effect, 5) Finally, tamoxifen, a selective partial AF-1 activator of ERα, is suf-
ficient to prevent the hyperplasia. Altogether, we demonstrate here, for the
first time, that ERαAF1 activation is both necessary and sufficient to prevent
post-injury arterial smooth muscle cell proliferation, in striking contrast to its
stimulatory action on the endometrial epithelium. This underlines the exquisite
tissue-specific actions of ERα subfunctions as well as of selective ER modu-
lators, and shed some light on one of the most intriguing mysteries of biology
of estrogens.
